American Society of Clinical Oncology

SHERPA: White

People

  1. Modi
    Modi
  2. Hudis
    Hudis
  3. Lake
    Lake
  4. D'Andrea-Carlino
    D'Andrea-Carlino
  5. Dang
    Dang
  6. Goldfarb
    Goldfarb
  7. Norton
    Norton
  8. Chandarlapaty
    Chandarlapaty
  9. Fornier
    Fornier
  10. Iyengar
    Iyengar

Groups

  1. Breast Medicine Service (9)
  2. Department of Medicine (9)
  3. Solid Tumor Oncology Division (9)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  5. Survivorship Research (8)
  6. Epidemiology and Biostatistics (7)
  7. Biostatistics Service (6)
  8. Population Sciences Research Program (6)
  9. GSK Faculty (5)
  10. Health Outcomes Research Group (5)
Search Within
  1. "Jose Baselga"
  2. "Shanu Modi"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (1)
Groups
  1. Breast Medicine Service (9)
  2. Department of Medicine (9)
  3. Solid Tumor Oncology Division (9)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (8)
  5. Survivorship Research (8)
  6. Epidemiology and Biostatistics (7)

More Groups

People
  1. Jose Baselga (9)
  2. Shanu Modi (9)
  3. Clifford Hudis (8)
  4. Diana Lake (6)
  5. Maura Dickler (6)
  6. Chau Dang (5)

More People

Years
  1. 2018 (2)
  2. 2017 (1)
  3. 2015 (2)
  4. 2014 (4)
Publications
  1. Journal of Clinical Oncology (9)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1
    Meeting Abstract

    Baselga, J.; Tamura, K.; Yamashita, T.; Modi, S.; Tokunaga, E.; Ito, Y.; Iwata, H.; Charif, M.; Lee, C. C.; Sugihara, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save